Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 70,114 shares at $26.48 ($1.8M) on 2024-03-18, disclosed to the SEC on 2024-03-20.
Scheduled sale ($1.8M) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.74 | 27,476 | $707K | 38.9% |
| 2 | $25.74 | 27,476 | $707K | 38.9% |
| 3 | $26.48 | 7,581 | $201K | 11.1% |
| 4 | $26.48 | 7,581 | $201K | 11.1% |
| Total | $25.90 avg | 70,114 | $1.8M | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2023-12-07 | $331K | — | Filing → |